著者

Takao Fujisawa Terufumi Shimoda Keisuke Masuyama Kimihiro Okubo Kohei Honda Mitsuhiro Okano Toshio Katsunuma Atsuo Urisu Yasuto Kondo Hiroshi Odajima Kazuyuki Kurihara Makoto Nagata Masami Taniguchi Shoichiro Taniuchi Satoru Doi Tomoshige Matsumoto Shoji Hashimoto Akihiko Tanaka Kensuke Natsui Nahoko Abe Hideki Ozaki

出版者

Japanese Society of Allergology

雑誌

Allergology International (ISSN:13238930)

巻号頁・発行日

vol.67, no.3, pp.347-356, 2018 (Released:2018-07-28)

参考文献数

49

被引用文献数

7

---

Background: To evaluate the long-term safety of subcutaneous immunotherapy with TO-204, a standardized house dust mite (HDM) allergen extracts, we conducted a multicenter, open label clinical trial.Methods: Japanese patients aged 5-65 years were eligible for the study, if they had HDM-induced allergic rhinitis (AR), allergic bronchial asthma (BA), or both. TO-204 was administered in a dose titration scheme, and the maintenance dose was determined according to the predefined criteria. The treatment period was 52 weeks, and patients who were willing to continue the treatment received TO-204 beyond 52 weeks. This clinical trial is registered at the Japan Pharmaceutical Information Center (Japic CTI-121900).Results: Between July 2012 and May 2015, 44 patients (28 with AR and 16 with allergic BA) were enrolled into the study. All patients were included in the analysis. The duration of treatment ranged from 23 to 142 weeks and the median maintenance dose was 200 Japanese allergy units (JAU). Adverse events occurred in 22 patients (50%). The most common adverse event was local reactions related to the injection sites. Four patients experienced anaphylactic reactions when they were treated with the dose of 500 JAU. Two patients experienced anaphylactic shock with the doses of 1000 JAU at onset. These 6 patients could continue the study with dose reduction.Conclusions: Safety profile of TO-204 was acceptable in Japanese patients with HDM-induced AR or allergic BA. Higher doses should be administered carefully, because the risk of anaphylaxis increased at doses of 500 or 1000 JAU.

著者

Risa Tamagawa-Mineoka Koji Masuda Akiko Yagami Masashi Nakamura Nayu Sato Kayoko Matsunaga Norito Katoh

出版者

Japanese Society of Allergology

雑誌

Allergology International (ISSN:13238930)

巻号頁・発行日

vol.67, no.3, pp.427-429, 2018 (Released:2018-07-28)

参考文献数

13

被引用文献数

8

著者

倉島 一喜 小川 晴彦 大家 多喜雄 藤村 政樹 松田 保 小林 勉

出版者

Japanese Society of Allergology

雑誌

アレルギー (ISSN:00214884)

巻号頁・発行日

vol.40, no.2, pp.160-163, 1991-02-28 (Released:2017-02-10)

---

喘息発作では粘液分泌の亢進, 粘液線毛輸送系の障害が認められ, 粘液栓の形成や末梢気道の閉塞をきたすと考えられる. サーファクタントは粘稠なゲル層をゾル層と開離させるほか, 末梢気道の開存性に重要な役割を果たしていると考えられる. 今回我々は喘息患者の発作時にサーファクタント吸入療法を行い, その効果について検討した. 方法は喘息発作にて来院した患者11名を無作為に次の2群に分けて治療した. 対照群5名では生食1mlをジェットネブライザーにて吸入し, サーファクタント治療群6名ではサーファクタント TA 10mg(1ml生食に懸濁)を同様の方法で吸入した. 両群とも投与前後で呼吸機能, ガス分析の測定を行い薬剤の効果を検討した. その結果, 喘息発作時, 生食吸入群では, FVC, FEV_<10>, MMF, PaO_2に有意な変化はみられなかった. サーファクタント治療群では吸入後FVC, FEV_<10>, MMF, PaO_2はそれぞれ11.7%, 27.3%, 33.2%, 13.4%上昇した. またPaCO_2には有意な変化は認められなかった. 以上より喘息発作時においてはサーファクタント吸入療法の有用性が示唆された.

著者

Yuki Nakamura Kayoko Ishimaru Atsuhito Nakao

出版者

Japanese Society of Allergology

雑誌

Allergology International (ISSN:13238930)

巻号頁・発行日

vol.69, no.2, pp.296-299, 2020 (Released:2020-04-17)

参考文献数

9

被引用文献数

5

著者

坂井 恵子 奥山 治美 島崎 弘幸 片桐 雅博 鳥居 新平 松下 隆 馬場 駿吉

出版者

Japanese Society of Allergology

雑誌

アレルギー (ISSN:00214884)

巻号頁・発行日

vol.43, no.1, pp.37-43, 1994-01-30 (Released:2017-02-10)

被引用文献数

1

---

血漿総脂質とリン脂質におけるリノール酸の割合がアトピー患者の方が同年齢の健常者より有意に多く, オレイン酸は少なかった. トリアシルグリセロール(中性脂質)分画ではn-3/n-6比がアトピー患者で有意に低かったが, n-6系列のγ-リノレン酸やアラキドン酸の割合は両群間に有意な差が認められなかった. 以上の結果より, アトピー患者でデルタ6-不飽和化酵素活性が低下している根拠はみられなかった. むしろ, 身体のアレルギー反応性を抑制するには食事脂質のn-3/n-6比を上げることが有効である可能性を論じた.

著者

Kenji Matsumoto Hirohisa Saito

出版者

Japanese Society of Allergology

雑誌

Allergology International (ISSN:13238930)

巻号頁・発行日

vol.62, no.3, pp.291-296, 2013 (Released:2013-09-14)

参考文献数

60

被引用文献数

37

---

Results from recent epidemiological studies strongly suggest that ingestion of food promotes immune tolerance to food antigens, whereas exposure to food antigens through skin leads to allergic sensitization. A "dual-allergen-exposure hypothesis" has been proposed to explain those findings. However, several other recent studies have demonstrated that some allergic diseases can be successfully treated by recurrent epicutaneous exposure to allergens. At a glance, these two sets of findings seem to be contradictory, but we think they provide important clues for understanding the mechanisms behind the allergy march. Here, we propose that per-"eczema"tous sensitization drives the allergy march, and we introduce results from several published studies in support of this hypothesis. We hope that this review may help in establishment of new strategies for preventing the allergy march in the near future.

著者

Kiyotaka Ohtani Sakura Sato Akinori Syukuya Tomoyuki Asaumi Kiyotake Ogura Yumi Koike Katsuhito Iikura Noriyuki Yanagida Takanori Imai Motohiro Ebisawa

出版者

Japanese Society of Allergology

雑誌

Allergology International (ISSN:13238930)

巻号頁・発行日

vol.65, no.2, pp.153-157, 2016 (Released:2016-04-29)

参考文献数

18

被引用文献数

51

---

Background: Hen's egg (HE) allergy develops during infancy. We investigated tolerance acquisition in Japanese children allergic to HE aging <6 years. Methods: In this retrospective study, 226 children born in 2005 with a history of immediate-type HE allergy underwent an oral food challenge (OFC). Tolerance was defined as no reaction to an OFC with half of whole heated HE or accidental HE consumption at home. Participants were divided into three groups based on age at tolerance acquisition: group I (<3 years) (n = 66), group II (3-6 years) (n = 98), and group III (prolonged allergic groups) (n = 62). Results: Tolerance acquisition occurred in 30% (66/226) by 3 years of age, 59% (133/226) by 5 years of age, and 73% (164/226) at 6 years of age. At 3 years, incidences of allergy-related complications (bronchial asthma, p = 0.02; atopic dermatitis, p = 0.04) were higher in the group III than in the group I. Anaphylaxis to any food occurred more frequently in the group III than in the group I (p = 0.03); anaphylaxis to HE was more common in the group III (p = 0.04). Egg white (EW)- and ovomucoid (OM)-specific immunoglobulin E (IgE) levels were higher in the group III than in the group I (p < 0.05). Conclusions: The group III experienced HE-related anaphylaxis and complications more frequently and exhibited sustained, high EW- and OM-specific IgE levels.

著者

Masutaka Furue Takahito Chiba Gaku Tsuji Dugarmaa Ulzii Makiko Kido-Nakahara Takeshi Nakahara Takafumi Kadono

出版者

Japanese Society of Allergology

雑誌

Allergology International (ISSN:13238930)

巻号頁・発行日

vol.66, no.3, pp.398-403, 2017 (Released:2017-07-25)

参考文献数

113

被引用文献数

198

---

Atopic dermatitis (AD) is a chronic or chronically relapsing, eczematous, severely pruritic skin disorder mostly associated with IgE elevation and skin barrier dysfunction due to decreased filaggrin expression. The lesional skin of AD exhibits Th2- and Th22-deviated immune reactions that are progressive during disease chronicity. Th2 and Th22 cytokines further deteriorate the skin barrier by inhibiting filaggrin expression. Some IgEs are reactive to self-antigens. The IgE autoreactivity may precipitate the chronicity of AD. Upon activation of the ORAI1 calcium channel, atopic epidermis releases large amounts of thymic stromal lymphopoietin (TSLP), which initiates the Th2 and Th22 immune response. Th2-derived interleukin-31 and TSLP induce an itch sensation. Taken together, TSLP/Th2/Th22 pathway is a promising target for developing new therapeutics for AD. Enhancing filaggrin expression using ligands for the aryl hydrocarbon receptor may also be an adjunctive measure to restore the disrupted barrier function specifically for AD.

著者

Arianna Dondi Giampaolo Ricci Paolo M. Matricardi Andrea Pession

出版者

Japanese Society of Allergology

雑誌

Allergology International (ISSN:13238930)

巻号頁・発行日

vol.64, no.2, pp.203-205, 2015 (Released:2015-04-13)

参考文献数

15

被引用文献数

7

著者

Toshinori Bito Yu Sawada Yoshiki Tokura

出版者

Japanese Society of Allergology

雑誌

Allergology International (ISSN:13238930)

巻号頁・発行日

vol.61, no.4, pp.539-544, 2012 (Released:2012-12-12)

参考文献数

58

被引用文献数

37

---

Cholinergic urticaria (CU) has clinically characteristic features, and has been frequently described in the literature. However, despite its comparatively old history, the pathogenesis and classification remains to be clarified. CU patients are occasionally complicated by anhidrosis and/or hypohidrosis. This reduced-sweat type should be included in the classification because the therapeutic approaches are different from the ordinary CU. It is also well-known that autologous sweat is involved in the occurrence of CU. More than half of CU patients may have sweat hypersensitivity. We attempt to classify CU and address the underlying mechanisms of CU based on the published data and our findings. The first step for classification of CU seems to discriminate the presence or absence of hypersensitivity to autologous sweat. The second step is proposed to determine whether the patients can sweat normally or not. With these data, the patients could be categorized into three subtypes: (1) CU with sweat hypersensitivity; (2) CU with acquired anhidrosis and/or hypohidrosis; (3) idiopathic CU. The pathogenesis of each subtype is also discussed in this review.